Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function

Experimental Biology and Medicine

Volumn 233, Issue 8, 2008, Pages 968-979

  Zagon, Ian S ^a,c   Donahue, Renee N ^a   Rogosnitzky, Moshe ^b   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b MedInsight ^*  (Israel)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Cancer; Cell proliferation; Imiquimod; Immunity; Opioid growth factor

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GROWTH FACTOR RECEPTOR; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; OPIATE; OPIOID GROWTH FACTOR RECEPTOR; RESIQUIMOD; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; METHIONINE ENKEPHALIN RECEPTOR; METHIONINE-ENKEPHALIN RECEPTOR; OPIATE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL DIVISION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BINDING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; MEDICAL TECHNOLOGY; PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; TECHNOLOGY; TISSUE CULTURE; UPREGULATION; ADENOCARCINOMA; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEAD AND NECK TUMOR; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNITY; PANCREATIC NEOPLASMS; RECEPTORS, OPIOID; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 50649120876     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0802-RM-58     Document Type: Article

References (33)

1. Stanley MA. Imiquimod and the imidazoquinolones: mechanisms of action and therapeutic potential. Clin Exp Dermatol 27:571-577, 2002.
2. Sauder DN. Imiquimod: modes of action. Brit J Dermatol 149 (Suppl. 66):5-8, 2003.
3. Oldfield V, Keating GM, Perry CM. Imiquimod. In superficial basal cell carcinoma. Amer J Clin Dermatol 6:195-200, 2005.
4. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 21:1-14, 1999.
5. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinoline. Cancer Res 52:3528-3533, 1992.
6. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol 3:196-200, 2002.
7. Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schön MP. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95:1138-1149, 2003.
8. Urosevic M, Oberholzer PA, Maier T, Hafner J, Laine E, Slade H, Benninghoff B, Burg G, Dummer R. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-α? Clin Cancer Res 10:4959-4970, 2004.
9. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev 38:351-376, 2002.
10. McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 14:991-998, 1999.
11. Zagon IS, Hytrek SD, McLaughlin PJ. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Amer J Physiol 271:R511-R518, 1996.
12. Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 14:577-584, 1999.
13. Zagon IS, McLaughlin PJ. Opioid growth factor, opioids, and differentiation of human cancer cells. Neuropeptides 39:495-505, 2005.
14. Zagon IS, Rahn KA, McLaughlin PJ. Opioids and migration, chemo-taxis, invasion, and adhesion of human cancer cells. Neuropeptides 41: 441-452, 2007.
15. Zagon IS, McLaughlin PJ. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 37:79-88, 2003.
16. Zagon IS, McLaughlin PJ. Endogenous opioids regulate growth of neural tumor cells in culture. Brain Res 490:14-25, 1989.
17. Zagon IS, McLaughlin PJ. Endogenous opioid systems regulate cell proliferation in the developing rat brain. Brain Res 412:68-72, 1987.
18. Zagon IS, Roesener CD, Verderame MF, Levin RJ, McLaughlin PJ. Cell cycle regulation of human neoplasias by opioid growth factor (OGF). Int J Oncology 17:1053-1061, 2000.
19. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The opioid growth factor (OGF) and OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res 67:10511-10518, 2007.
20. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 7:5, 2008.
21. Zagon IS, Ruth TB, McLaughlin PJ. Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. The Anat Rec 282A:24-37, 2005.
22. Meyer T, Nindl I, Schmook T, Ulrich C, Sterry W, Stockfleth E. Induction of apoptosis by toll-like receptor-7 agonist in tissue cultures. Brit J Dermatol 149 (Suppl. 66):9-13, 2003.
23. Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H, Scherr DS. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol 177:2347-2351, 2007.
24. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrobial Chemother 48:751-755, 2001.
25. Zagon IS, Sassani JW, Malefyt KJ, McLaughlin PJ. Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol 124:1620-1624, 2006.
26. Zagon IS, Sassani JW, Verderame MF, McLaughlin PJ. Particle-mediated gene transfer of OGFr cDNA regulates cell proliferation of the corneal epithelium. Cornea 24:614-619, 2005.
27. Zagon IS, Verderame MF, Hankins J, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer. Int J Oncol 30:775-783, 2007.
28. McLaughlin PJ, Verderame MF, Hankins J, Zagon IS. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med 19:421-428, 2007.
29. Arany I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 43:55-63, 1999.
30. Sidbury R, Neuschler N, Neuschler E, Sun P, Wang X-Q, Miller R, Tomai M, Puscasiu E, Gugneja S, Paller AS. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 121:1205-1209, 2003.
31. Burns RP, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 94:13-23, 2000.
32. Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS. Treatment of advanced pancreatic cancer with opioid growth factor. Anti-Cancer Drugs 15:203-209, 2004.
33. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Amer Acad Dermatol 41:1002-1007, 1999.